MedPath

PDS Biotech's PDS0101 and Keytruda Combination Therapy to Enter Phase 3 Trial for HPV16-Positive Cancers

• PDS Biotechnology is set to initiate the VERSATILE-003 Phase 3 trial in Q1 2025, evaluating the combination of PDS0101 and Keytruda. • The trial will focus on patients with HPV16-positive head and neck squamous cell carcinoma (HNSCC). • The analysts believe Merck's Keytruda success in KEYNOTE-689 study is unlikely to affect the Versamune double combination since KEYNOTE-689 enrolled very few HIV16+ patients. • Alliance Global Partners maintains a Buy rating on PDSB, though lowered the price target to $4.50 from $7.

PDS Biotechnology is advancing its combination therapy, PDS0101 and Keytruda (pembrolizumab), into a Phase 3 registrational trial, named VERSATILE-003, for the treatment of HPV16-positive cancers. The trial is expected to commence in the first quarter of 2025.
The VERSATILE-003 trial will evaluate the efficacy and safety of PDS0101 in combination with Merck’s Keytruda in patients with head and neck squamous cell carcinoma (HNSCC) who are positive for the human papillomavirus 16 (HPV16).
Analyst Perspective
Alliance Global Partners has adjusted its price target for PDS Biotechnology to $4.50, down from $7, while reaffirming a Buy rating on the company's stock. This decision follows PDS Biotechnology's announcement of its Q3 results and details regarding the design and initiation of the VERSATILE-003 trial.
The firm suggests that recent developments with Merck’s Keytruda in the HNSCC space, specifically its success in the KEYNOTE-689 study, are unlikely to impact the Versamune double combination. This is because the KEYNOTE-689 study included a limited number of HPV16-positive patients.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

PolyPid's D-PLEX100 Poised for Potential 2026 Launch After SHIELD II Trial Update

PolyPid's SHIELD II Phase 3 trial for D-PLEX100, targeting surgical site infections, is set to conclude enrollment at 800 patients following DSMB recommendation.
Top-line results from the SHIELD II trial are expected in Q2 2025, with a rolling NDA submission to the FDA planned for Q3 2025.

Vertex Pharmaceuticals Faces Mixed Outlook for Suzetrigine After Phase 2 Data

Vertex Pharmaceuticals' Suzetrigine showed less promising Phase 2 results for lumbosacral radiculopathy, reducing the probability of success from 50% to 15%.
Despite the LSR setback, optimism remains high for Suzetrigine in acute pain treatment, with anticipated FDA approval based on positive Phase 3 trial outcomes.

Ideaya Biosciences Faces Stock Lows Amidst Pipeline Developments and Analyst Optimism

Ideaya Biosciences' stock hit a 52-week low, reflecting broader biotech sector challenges despite a strong financial position and ongoing R&D efforts.
The company is advancing its pipeline with a Phase 1 trial for IDE161 plus KEYTRUDA in endometrial cancer and plans for SHR-4849 in lung cancer.

PDS Biotech's VERSATILE-003 Phase 3 Trial for HPV16-Positive Head and Neck Cancer to Initiate Q1 2025

PDS Biotech reaffirms its plan to initiate the VERSATILE-003 Phase 3 trial in Q1 2025, evaluating Versamune HPV plus pembrolizumab for recurrent/metastatic HPV16-positive head and neck cancer.
The FDA has cleared the updated clinical protocol for the trial, which maintains statistical power with approximately 350 patients and a 2:1 randomization.

PDS Biotech's Versamune HPV Shows Promise in HPV16-Positive Cancers, Phase III Trial Planned

PDS Biotechnology's VERSATILE-003 Phase III trial, evaluating Versamune HPV with pembrolizumab, is set to begin in early 2025, with interim data expected six months after enrollment completion.
Encouraging VERSATILE-002 data reveals improved overall survival and objective response rates with Versamune HPV compared to pembrolizumab alone in HPV16-positive cancers.

Allogene Pauses Cema-Cel Trial Enrollment, Prioritizes Other Programs

Allogene Therapeutics halts new patient enrollment in the Phase 1 ALPHA2 study of cema-cel for relapsed/refractory Chronic Lymphocytic Leukemia (r/r CLL) due to slow enrollment.
Piper Sandler reduces Allogene's price target to $9, excluding cema-cel revenue in CLL from its valuation model, while maintaining an Overweight rating.

PDS Biotech Updates Phase 3 VERSATILE-003 Trial Design for HPV16-Positive HNSCC

PDS Biotechnology has updated the Phase 3 VERSATILE-003 trial design for HPV16-positive recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC), increasing the patient target to approximately 350.
The updated design maintains a 2:1 randomization and median overall survival as the primary endpoint, aligning with the FDA agreement on registrational design.

PDS Biotech Announces Clinical Program Updates and Q3 2024 Financial Results

PDS Biotech is advancing the VERSATILE-003 Phase 3 trial of Versamune HPV + pembrolizumab for recurrent/metastatic HPV16-positive head and neck squamous cell cancer (HNSCC).
Updated trial design for VERSATILE-003 includes approximately 350 patients and maintains key endpoints, with potential for earlier data readouts and reduced costs.

Paradigm Biopharmaceuticals Advances Phase 3 Trial for Osteoarthritis Treatment

Paradigm Biopharmaceuticals is preparing to submit a revised Phase 3 trial protocol to the FDA, focusing on patient convenience and cost reduction.
The company has selected four global CROs and anticipates commencing patient enrollment in Australia by early 2025.

Vir Biotechnology Faces Setbacks in HBV and Influenza Trials, Stock Downgraded

Vir Biotechnology's stock declined 54% year-to-date due to lackluster results from influenza A and hepatitis B (HBV) trials, leading to a downgrade by Bank of America.
Upcoming results in Q4 2023 for the triple combination treatment of Vir-2218, Vir-3434, and PEG-INF in HBV are crucial, requiring functional cure rates over 40-50% for commercial viability.

Reference News

[1]
PDS Biotechnology price target lowered to $4.50 from $7 at Alliance Global Partners
markets.businessinsider.com · Nov 15, 2024

Alliance Global Partners lowers PDS Biotechnology's price target to $4.50 from $7, maintaining a Buy rating. The firm an...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy